Novartis

$89.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.66 (+0.74%) Today
+$0.19 (+0.21%) As of 4:04 AM EST after-hours

Why Robinhood?

You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!

About NVS

Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Employees
125,161
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1996
Market Cap
204.29B
Price-Earnings Ratio
17.42
Dividend Yield
2.15
Average Volume
1.68M
High Today
$89.59
Low Today
$89.20
Open Price
$89.24
Volume
807.34K
52 Week High
$96.31
52 Week Low
$74.97

Collections

NVS News

Benzinga19h

Global Analgesics Market Report 2020 with Profiles on Key Players Bayer Healthcare, Pfizer, Sanofi, Johnson & Johnson and Novartis

Dublin, Nov. 12, 2019 (GLOBE NEWSWIRE) -- The "Analgesics Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The global a
48
ReutersNov 12

BRIEF-Novartis cites positive data for Cosentyx in axial spondyloarthritis

Nov 12 (Reuters) - Novartis AG: * NEW NOVARTIS PREVENT DATA SHOW COSENTYX DELIVERS EARLY RELIEF IN AXIAL SPONDYLOARTHRITIS * 42.2% OF PATIENTS WITH NON-RADIOG
8

NVS Earnings

$1.20
$1.27
$1.34
$1.41
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Jan 29, Pre-Market

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.